Caribou Inks Drug Target Research, Investment Agreements with Novartis | GenomeWeb

NEW YORK (GenomeWeb) – Caribou Biosciences announced today that it has signed a deal under which it will use its CRISPR/Cas 9 gene-editing technology for the discovery and validation of new drug targets for Novartis.

Concurrent with the agreement, Novartis has also taken an undisclosed equity stake in Caribou through a Series A investment round.

Caribou will receive research funding from Novartis under the one-year term of the agreement, and it has also provided Novartis with an option to non-exclusively license its CRISPR/Cas 9 platform for research applications.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.